Acticor Biotech, a Paris, France-based clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, closed a €1.7m equity financing.
The round was led by Primer Capital with participation from historical shareholders Anaxago, CapDecisif Management and private investors.
The company, which also received grants from Concours Mondial de l’Innovation for €2.2m, for a total of €3.9m, intends to use the funds to strengthen its cash position in the perspective of the preparation of the first clinical phase II for its lead candidate, ACT017.
Founded in 2013 as a spin-off of Inserm (Paris, France) and led by Dr Gilles Avenard, President, Acticor Biotech is developing an innovative drug for the treatment in the acute phase of ischemic stroke. The company develops a biologic drug candidate based on academic research on a platelet glycoprotein called GPVI. GPVI is a platelet receptor of collagen and polymerized fibrin. The drug candidate ACT017 is a humanized fragment of monoclonal antibody which binds to GPVI and inhibits platelet adhesion and aggregation on collagen and polymerized fibrin.